Gilead Reports Phase 3 Data for Iptacopan in Cervical cancer

Gilead today announced Phase 3 results for iptacopan in patients with cervical cancer. The study demonstrated that iptacopan achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of cervical cancer and support the continued development of iptacopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.